Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 2/20 | 0.30 |
| ▸ | ACHE | P22303 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20173486 | 0.90 | SSTR4 (0.31) | SSTR4 | |
| SCHEMBL23892821 | 0.90 | F2 (0.33) | FDPSBCHEACHEMAPTSSTR4 | |
| SCHEMBL20163447 | 0.88 | LSS (0.36) | SSTR4 | |
| SCHEMBL20173480 | 0.87 | CHEK2 (0.32) | SSTR4 | |
| SCHEMBL19485524 | 0.86 | LSS (0.31) | SSTR4 | |
| SCHEMBL18290069 | 0.86 | PDE1A (0.35) | MAPTRAB9A | |
| SCHEMBL29509125 | 0.86 | PDE1A (0.35) | MAPTRAB9A | |
| SCHEMBL18295981 | 0.85 | SSTR4 (0.31) | SSTR4 | |
| SCHEMBL20191131 | 0.83 | EPHX2 (0.30) | — | |
| SCHEMBL22149861 | 0.83 | LSS (0.37) | FDPSBCHEACHEMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033376-A1 | ESTROGEN RECEPTOR ANTAGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-02-03 | — | — | US | disclosed |
| EP-3889133-A1 | ESTROGEN RECEPTOR ANTAGONIST | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020125640-A1 | ESTROGEN RECEPTOR ANTAGONIST | 正大天晴药业集团股份有限公司 | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033376-A1 | ESTROGEN RECEPTOR ANTAGONIST | ESR1, GPER1, ESR2 | FDPS 4618/4885BCHE 2300/4885ACHE 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.